Genitourinary Cancer News

MADRID — Toni Choueiri, MD, talked with Healio about some of the new kidney cancer data “that could be practice-changing and, for sure, practice-informing” presented at ESMO Congress.

MADRID — In a video interview with Healio, Sumanta (Monty) Pal, MD, FASCO, spoke about the STELLAR-304 clinical trial for patients with non-clear cell renal cell carcinoma at ESMO Congress.

MADRID — In this video, Sumanta (Monty) Pal, MD, FASCO, shared his excitement about belzutifan data, a “big development” of ESMO Congress, in the renal cell carcinoma space.

Pembrolizumab as adjuvant therapy significantly prolonged OS compared with placebo among adults with renal cell carcinoma who underwent nephrectomy with or without resection of metastatic lesions, according to the agent’s manufacturer.

Researchers at UT Southwestern Medical Center have introduced a new metric that may be useful in predicting which patients are likely to develop immunotherapy toxicity.

A subcutaneous nivolumab formulation showed noninferior pharmacokinetics and objective response rates compared with IV nivolumab in patients with advanced or metastatic clear cell renal cell carcinoma, according to the agent’s manufacturer.

MADRID — A two-drug combination improved outcomes compared with first-line chemotherapy for adults with locally advanced or metastatic urothelial carcinoma, according to findings presented at ESMO Congress.

MADRID — A novel T-cell engager appeared safe and exhibited efficacy as treatment for neuroendocrine tumors, according to study results presented at ESMO Congress.

In this episode, host Shikha Jain, MD, speaks with Pia Chowdry, MD, about access to care in rural communities, how physicians can present information to patients and their caregivers and more.

Fred Hutchinson Cancer Center appointed Lawrence Fong, MD, as scientific director of the Immunotherapy Integrated Research Center.